The arrival of biosimilar adalimumab in European markets has been cause for enthusiasm among those seeking greater patient access and lower costs for the treatment of rheumatoid arthritis (RA). However, AbbVie (maker of the reference adalimumab, Humira) has revealed that its oral Janus kinase inhibitor, upadacitinib, outperformed both placebo and adalimumab in a phase 3 study.
The arrival of biosimilar adalimumab in European markets has been cause for enthusiasm among those seeking greater patient access and lower costs for the treatment of rheumatoid arthritis (RA). However, AbbVie (maker of the reference adalimumab, Humira) has revealed that its oral Janus kinase (JAK) inhibitor, upadacitinib, outperformed both placebo and adalimumab in a phase 3 study.
The results of the SELECT-COMPARE trial, which AbbVie first announced in topline in April 2018, were presented during the American College of Rheumatology (ACR)’s annual meeting, held in Chicago, Illinois, October 19-24, 2018.
In the trial, 1629 patients with active RA despite methotrexate treatment were randomized 2:2:1 to receive 15 mg of upadacitinib daily, placebo, or 40 mg of adalimumab every other week, all while continuing methotrexate. The study’s primary end points were noninferiority and superiority of upadacitinib versus adalimumab at week 12 and radiographic inhibition for upadacitinib versus placebo at week 26.
In total, 91% of patients completed the full 26 weeks. At week 12, 70.5% of those receiving upadacitinib and 36.4% of those receiving placebo achieved ACR criteria for 20% improvement (ACR20); 28.7% and 6.1%, respectively, had a disease activity score in a count of 28 joints plus C-reactive protein (DAS28-CRP) of under 2.6. At week 26, more patients receiving upadacitinib had no radiographic progression than patients receiving placebo (83.5% vs 76.0%).
Upadacitinib also demonstrated superiority versus adalimumab at week 12 for ACR50 (45.2% vs 29.1%) and for DAS28-CRP of 3.2 or less (45.0% vs 28.7%). Furthermore, upadacitinib was superior in terms of reduction of pain and improvement in quality of life as measured by the Health Assessment Questionnaire Disability Index.
The proportion of patients with adverse events (AEs) was higher for those given upadacitinib than those given placebo, but similar to those given adalimumab. Notably, thromboembolic events were similar across the 3 arms; 6 venous thromboembolic events occurred, 1 in the placebo arm, 2 in the upadacitinib arm, and 3 in the adalimumab arm. In a previous phase 3 study in the same clinical program, SELECT-MONOTHERAPY, some concerns arose about the safety of the drug; 1 patient taking the study drug died of a hemorrhagic stroke, caused by a ruptured aneurysm.
The positive data from this phase 3 trial may to support AbbVie in its effort to find a fresh foothold in the RA market as 4 EU competitors to Humira begin to sell their products, and as sales will begin for adalimumab biosimilars in the United States in 2023.
Reference
Fleischmann R, Pangan AL, Mysler E, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Presented at: American College of Rheumatology 2018 Meeting; October 19-24, 2018; Chicago, Illinois. Abstract 890. https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-study-comparing-upadacitinib-to-placebo-and-to-adalimumab-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate/.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.